News

Delhi High Court asks drug regulator to look into concerns over approval for weight-loss drugs
A PIL has claimed that licences for these drugs were issued without adequate data or India-specific trials and studies, ...
Semaglutide Market Forecast Report 2025-2033 Growth Accelerates Amid Rising Awareness, Regulatory Approvals, And Strong Pipeline Advancements
The Semaglutide market is projected to expand from US$ 27.15 billion in 2024 to US$ 61.7 billion by 2033, with a CAGR of 9.55% from 2025. Driven by r ...
Biocon climbs 3% on plans to file approvals for generic weight-loss drug
Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...
Biocon aims to lead copycat Wegovy sales in Canada from next year
Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...
Biocon eyes early lead in generic Wegovy, Ozempic sales in Canada from 2026
The Bengaluru-based company is seeking approval of generic Ozempic by September from Canadian authorities, and also in some ...
Biocon eyes Canadian bonanza from generics of weight-loss 'super-drugs' Ozempic and Wegovy
Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key ...
How Novo Nordisk misread the US market for its weight loss sensation
Top executives ignored warnings that the company was not sufficiently prepared for the launch of its weight-loss drug Wegovy, ...
Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide
Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...
Dagens.com on MSN6d
“Very Dangerous”: Americans Are Turning to ‘Homemade’ Weight-Loss Drugs Amid Soaring Costs
Facing limited insurance coverage and unaffordable prices for drugs like Wegovy and Zepbound, Americans are importing active ...